NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00111319,VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma,https://clinicaltrials.gov/study/NCT00111319,,COMPLETED,The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously untreated multiple myeloma.,NO,Multiple Myeloma,DRUG: bortezomib,Time to progression,"Progression-free survival, overall response rate, overall survival, time to first response, duration of response, CR rate, and patient reported outcomes as assessed using the EORTC QLQ-C30, FACIT-F and EQ-5D instruments.",,"Millennium Pharmaceuticals, Inc.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",ALL,"ADULT, OLDER_ADULT",PHASE3,,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,26866138-MMY-3002,2004-12,2007-07,,2005-05-20,,2009-03-26,"Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, 46254, United States",
